By Colin Kellaher
Immunovant unveiled a series of executive changes that more closely aligns the clinical-stage immunology company with majority shareholder Roivant Sciences.
Immunovant on Monday said Pete Salzmann has retired as chief executive and a director of the New York company, and that Eric Venker, a board member who also serves as Roivant's president, has stepped in as CEO.
The company said Salzmann, who joined as CEO in 2019, will be eligible for severance benefits as part of a separation agreement.
Immunovant also said Renee Barnett has stepped down as chief financial officer and has been succeeded by Tiago Girao, who has served as finance chief for multiple Roivant units since 2019.
The company said Barnett, 45 years old, will receive an annual base salary of $481,000 and an annual bonus with a target of 45% of his base pay, adding that it expects to sign a separation agreement with Barnett that includes severance benefits.
Immunovant said the executive changes are part of a broader strategic transition with Roivant that increases the pharmaceutical company's operational involvement and strategic oversight of Immunovant, which was spun out of Roivant in 1999.
Roivant still owns about 57% of Immunovant.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 21, 2025 07:44 ET (11:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。